Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.54 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | F10 | P00742 | 1/20 | 0.50 |
| ▸ | F12 | P00748 | 1/20 | 0.50 |
| ▸ | F7 | P08709 | 1/20 | 0.50 |
| ▸ | F3 | P13726 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20017352 | 0.88 | MEN1 (0.50) | KMT2AMEN1POLBGRIN2BGRIN1 | |
| SCHEMBL24022828 | 0.86 | NPC1 (0.61) | KMT2AMEN1POLBGRIN2BGRIN1 | |
| SCHEMBL22044257 | 0.86 | CYP2D6 (0.66) | KMT2AMEN1POLBGRIN2BGRIN1 | |
| SCHEMBL13770411 | 0.85 | KMT2A (0.52) | KMT2AMEN1POLBGRIN2BGRIN1 | |
| SCHEMBL26570936 | 0.82 | HPGD (0.47) | KMT2AMEN1POLBGRIN2BGRIN1 | |
| SCHEMBL18891443 | 0.82 | PBRM1 (0.55) | KMT2AMEN1POLBGRIN2BGRIN1 | |
| SCHEMBL24689825 | 0.82 | KMT2A (0.45) | KMT2AMEN1POLBGRIN2BGRIN1 | |
| SCHEMBL13978226 | 0.82 | KMT2A (0.45) | KMT2AMEN1POLBGRIN2BGRIN1 | |
| SCHEMBL18891357 | 0.81 | KMT2A (0.48) | KMT2AMEN1POLBGRIN2BGRIN1 | |
| SCHEMBL22044393 | 0.81 | PKM (0.61) | KMT2AMEN1POLBGRIN2BPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857636-B2 | Bio-orthogonal drug activation | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2024-01-02 | — | — | US | disclosed |
| US-20210162060-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2021-06-03 | — | — | US | disclosed |
| US-10967069-B2 | Bio-orthogonal drug activation | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2021-04-06 | — | — | US | disclosed |
| US-10927139-B2 | Chemically cleavable group | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2021-02-23 | — | — | US | disclosed |
| US-20210002320-A1 | CHEMICALLY CLEAVABLE GROUP | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2021-01-07 | — | — | US | disclosed |
| US-20190336612-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2019-11-07 | — | — | US | disclosed |
| US-9931408-B2 | Bio-orthogonal drug activation | KONINKLIJKE PHILIPS N.V. (NL) | 2018-04-03 | — | — | US | disclosed |
| WO-2017093263-A1 | PROCESS FOR PREPARING FUNCTIONALIZED 1,2,4,5-TETRAZINE COMPOUNDS | UNIVERSITE DE BOURGOGNE (FR) | 2017-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002320-A1 | CHEMICALLY CLEAVABLE GROUP | SQLE, CTRL, ENO1 | KMT2A 3847/4885MEN1 503/4885POLB 1691/4885 |
| US-10967069-B2 | Bio-orthogonal drug activation | JMJD7, KIT, PAICS | KMT2A 949/4885MEN1 3386/4885POLB 2540/4885 |
| US-20210162060-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | JMJD7, KIT, PAICS | KMT2A 949/4885MEN1 3386/4885POLB 2540/4885 |
| US-10927139-B2 | Chemically cleavable group | SQLE, CTRL, ENO1 | KMT2A 3934/4885MEN1 565/4885POLB 1630/4885 |
| US-20190336612-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | JMJD7, KIT, PAICS | KMT2A 949/4885MEN1 3386/4885POLB 2540/4885 |
| US-11857636-B2 | Bio-orthogonal drug activation | JMJD7, KIT, PAICS | KMT2A 949/4885MEN1 3386/4885POLB 2540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.